Press releaseMar 29, 2026Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta…
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study 1 40.7% o...
Publisher
Switzerland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study 1 40.7% o...
Source route
Continue on novartis.com
Leave the platform to read the original full article on the publisher site.
Source: Novartis News
Scope: Industry
Related coverage
More related coverage
Shionogi Announces Corporate Reorganization and Personnel Reassignment (Effective April 1, 2026)
OSAKA, Japan, February 13, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO...
Mar.02.2026CorporateAnnouncement on Changes of the Board of Directors and Corporate Officers
Osaka, Japan, March 2, 2026 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President an...
News and Events
Stay informed with the latest Sanofi investor news, financial results, earnings calls, and key event...
AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
Data highlights efficacy and safety of risankizumab in psoriatic disease, including high impact area...